[Skip to Navigation]
Views 818
Citations 0
Comment & Response
April 23, 2020

Obesity Paradox in Patients With Non–Small Cell Lung Cancer Treated With Immunotherapy

Author Affiliations
  • 1Huntsman Cancer Institute, Division of Urology, University of Utah, Salt Lake City, Utah
  • 2Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
JAMA Oncol. 2020;6(6):940-941. doi:10.1001/jamaoncol.2020.0634

To the Editor We read with great interest the study by Kichenadasse et al1 in which the authors used individual patient-level data from 2110 clinical trial participants with locally advanced/metastatic non–small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors or chemotherapy to assess the association of body mass index (BMI) with survival outcomes and treatment-related toxic effects. The authors found that, among atezolizumab-treated patients, baseline BMI of 30 or greater was significantly associated with improved overall and progression-free survival compared with patients whose BMI was 18.5 to 29.9. Among atezolizumab-treated patients, obesity was not associated with an increased frequency of adverse events, and results did not differ by sex. These findings were not present in the chemotherapy-treated cohort. The authors concluded that “baseline BMI should therefore be considered as a stratification factor in future immune checkpoint inhibitor therapy trials.”1 Although the authors nicely demonstrate that BMI may be a predictive factor for patients with advanced NSCLC treated with immunotherapy, we believe that more research is needed prior to using BMI as a stratification factor for clinical trials.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words